Clinical-stage biopharmaceutical company Immunic (NSDQ:IMUX) announced that it is offering common stock shares for approximately $25 million. The offering includes nearly 2.2 million shares of common stock priced to the public at $11.40 per share, amounting to proceeds of $25 million before deducting fees and estimated offering expenses. In an SEC filing dated June 10, […]
immunic
Vital Therapies pulls the trigger on Immunic share swap
Vital Therapies (NSDQ:VTL) said today that it inked a deal to swap shares with Germany-based Immunic, transitioning its efforts to focus on Immunic’s pipeline of drugs for chronic inflammatory and autoimmune diseases. Once the deal is closed, Vital Therapies plans to operate under the name Immunic and trade on the Nasdaq market. Get the full story […]